Traj34: A Potential Drug Target for Cancer and Autoimmune Disorders

Target Name: TRAJ34

NCBI ID: G28721

TRAJ34

Other Name(s): T cell receptor alpha joining 34

Traj34: A Potential Drug Target for Cancer and Autoimmune Disorders

Traj34, also known as T cell receptor alpha joining 34, is a protein that is expressed in the T cells of the human body. It plays a crucial role in the immune system, specifically in the regulation of T cell responses. Traj34 is a potential drug target or biomarker for several diseases, including cancer, autoimmune disorders, and inflammatory diseases.

The immune system is a critical component of the body's defense against infection and disease. T cells, a type of immune cell, are responsible for cell-mediated immunity. They are able to recognize and respond to foreign substances in the body, including viruses, bacteria, and cancer cells. T cell receptor alpha joining 34 is a protein that is expressed in T cells and plays a critical role in the regulation of T cell responses.

Traj34 is a protein that is composed of two subunits, a heavy chain and a light chain. The heavy chain consists of 184 amino acids, while the light chain consists of 176 amino acids. The two subunits of Traj34 are held together by a disulfide bond, which is a covalent bond that is formed by the oxidation of a cysteine residue on one amino acid to a sulfur atom on the other amino acid.

Traj34 is expressed in T cells and is involved in the regulation of T cell responses. It is a critical receptor for the activation and proliferation of T cells. When a T cell encounters a foreign substance, such as a virus or a cancer cell, Traj34 is activated and causes the T cell to undergo a process called clonal expansion and differentiate into a specialized type of cell called an activation T cell. These activated T cells are able to recognize and respond to the foreign substance, leading to the immune response.

Traj34 is also involved in the regulation of T cell death. When a T cell is no longer needed or is damaged, Traj34 helps to ensure that it is eliminated from the body. This is important for maintaining the balance of T cells in the immune system and for preventing the formation of cancerous T cells.

In addition to its role in T cell regulation, Traj34 is also a potential drug target or biomarker for several diseases. For example, Traj34 has been shown to be involved in the development and progression of several types of cancer, including breast cancer, lung cancer, and colorectal cancer. It is also involved in the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

Traj34 is a protein that is expressed in T cells and plays a critical role in the immune system. It is a potential drug target or biomarker for several diseases, including cancer and autoimmune disorders. Further research is needed to fully understand the role of Traj34 in the immune system and its potential as a drug.

Protein Name: T Cell Receptor Alpha Joining 34

The "TRAJ34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets